{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:29:45Z","timestamp":1773797385377,"version":"3.50.1"},"reference-count":22,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"3","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: This study investigates the clinical significance of Solute Carrier Family 7 Member 11 (SLC7A11), Tumor Protein p53 (p53), c D3+ T cells, and CD8+ T cells in endometrial carcinoma (EC). By evaluating their expression patterns and correlations with histopathological parameters and patient outcomes, we aim to develop a prognostic risk model integrating these biomarkers. Methods: We enrolled 134 EC patients (observation group) diagnosed between February 2023 and January 2024 and 128 concurrent healthy controls, and were confirmed to have no endometrial abnormalities by gynecological examination and ultrasound. Quantitative and qualitative assessments were conducted to measure SLC7A11, p53, and CD3+\/CD8+ T cell levels. Diagnostic performance of individual and combined markers was analyzed using receiver operating characteristic (ROC) curves, while a logistic regression-based predictive model was developed. Associations of these biomarkers with EC histopathological features and 1-year survival outcomes were further evaluated. Results: Compared to controls, EC patients exhibited notable reductions in CD3+\/CD8+ T-cell infiltration but elevations in SLC7A11 and p53 expression (P&amp;lt;0.05). According to qualitative analysis, CD3 and CD8 positivity were similarly lower in tumor tissues than in adjacent normal tissue, whereas SLC7A11 and p53 staining were more frequent in malignant lesions (P &amp;lt;0.05). For EC diagnosis, the combined AUC of p53, SLC7A11, CD3+ T cells, and CD8+ T cells reached 0.883 (72.4% sensitivity, 88.3% specificity). Their combination also effectively predicted 1-year mortality risk (AUC = 0.889), with 82.4% sensitivity and 81.0% specificity. Conclusions: p53, SLC7A11, CD3+ T cells, and CD8+ T cells show intimate connections with EC. A diagnostic model incorporating these biomarkers enhances the accuracy of EC detection, offering improved clinical utility.<\/jats:p>","DOI":"10.5937\/jomb0-60128","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T08:24:36Z","timestamp":1756110276000},"page":"663-670","source":"Crossref","is-referenced-by-count":0,"title":["Correlations of P53, SLC7A11, CD3+ T cells, and CD8+ T cells with pathological features and prognosis in endometrial carcinoma: Insights from an Asian cohort"],"prefix":"10.5937","volume":"45","author":[{"given":"Yuanjie","family":"Lv","sequence":"first","affiliation":[{"name":"Cangzhou Central Hospital, Department of Pathology, Cangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cangzhou Central Hospital, Department of Pathology, Cangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cangzhou Central Hospital, Department of Pathology, Cangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[{"name":"Cangzhou Central Hospital, Department of Gynecology, Cangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongge","family":"Xing","sequence":"additional","affiliation":[{"name":"Cangzhou Central Hospital, Department of Pathology, Cangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Miao","sequence":"additional","affiliation":[{"name":"Cangzhou Central Hospital, Department of Pathology, Cangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet (London, England) 2022; 399(10333): 1412-28;","DOI":"10.1016\/S0140-6736(22)00323-3"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nature reviews Disease Primers 2021; 7(1): 88;","DOI":"10.1038\/s41572-021-00324-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"van den Heerik A, Horeweg N, de Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021; 31(4): 594-604;","DOI":"10.1136\/ijgc-2020-001822"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Koppula P Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 2021; 12(8): 599-620;","DOI":"10.1007\/s13238-020-00789-5"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wu Z, Zheng Y Sheng J, Han Y Yang Y Pan H, et al. CD3( + )CD4(-)CD8(-) (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer. Frontiers in Immunology 2022; 13: 816005;","DOI":"10.3389\/fimmu.2022.816005"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Zhang C, Liu J, Xu D, Zhang T, Hu W , Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. Journal of Molecular Cell Biology 2020; 12(9): 674-87;","DOI":"10.1093\/jmcb\/mjaa040"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Wang Z, Shu W , Zhao R, Liu Y, Wang H. Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3\/SLC7A11 axis. Apoptosis : an international journal on programmed cell death 2023; 28(7-8): 1168-83;","DOI":"10.1007\/s10495-023-01850-4"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics 2023; 13(4): 1421-42;","DOI":"10.7150\/thno.81847"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Galant N, Krawczyk P Monist M, Obara A, Gajek E, Grenda A, et al. Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection. Int J Mol Sci 2024; 25(11);","DOI":"10.3390\/ijms25115893"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Terzic M, Aimagambetova G, Kunz J, Bapayeva G, Aitbayeva B, Terzic S, et al. Molecular Basis of Endometriosis and Endometrial Cancer: Current Knowledge and Future Perspectives. Int J Mol Sci 2021; 22(17);","DOI":"10.3390\/ijms22179274"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Fang X, Zhang T, Chen Z. Solute Carrier Family 7 Member 11 (SLC7A11) is a Potential Prognostic Biomarker in Uterine Corpus Endometrial Carcinoma. International Journal of General Medicine 2023; 16: 481-97;","DOI":"10.2147\/IJGM.S398351"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biology 2022; 52: 102317;","DOI":"10.1016\/j.redox.2022.102317"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Wang Z, Zong H, Liu W , Lin W , Sun A, Ding Z, et al. Augmented ERO1 upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11. Journal of Experimental & Clinical Cancer Research: CR 2024; 43(1): 112;","DOI":"10.1186\/s13046-024-03039-2"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Saini KK, Chaturvedi P Sinha A, Singh MP Khan MA, Verma A, et al. Loss of PERK function promotes ferroptosis by downregulating SLC7A11 (System X c ) in colorectal cancer. Redox Biology 2023; 65: 102833;","DOI":"10.1016\/j.redox.2023.102833"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Liebl MC, Hofmann TG. The Role of p53 Signaling in Colorectal Cancer. Cancers (Basel) 2021; 13(9);","DOI":"10.3390\/cancers13092125"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Vermij L, L\u00e9on-Castillo A, Singh N, Powell ME, Edmondson RJ, Genestie C, et al. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022; 35(10): 475-83;","DOI":"10.1038\/s41379-022-01102-x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Jamieson A, Thompson EF Huvila J, Gilks CB, McAlpine JN. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021; 31(6): 907-13;","DOI":"10.1136\/ijgc-2020-002256"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Lei M, Zhang YL, Huang FY, Chen HY, Chen MH, Wu RH, et al. Gankyrin inhibits ferroptosis through the p53\/SLC7A11\/GPX4 axis in triple-negative breast cancer cells. Scientific Reports 2023; 13(1): 21916;","DOI":"10.1038\/s41598-023-49136-8"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Li R, Xu J, Wu M, Liu S, Fu X, Shang W , et al. Circulating CD 4(+) Treg, CD 8(+) Treg, and CD 3(+) ub T Cell Subpopulations in Ovarian Cancer. Medicina (Kaunas, Lithuania) 2023; 59(2);","DOI":"10.3390\/medicina59020205"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Feng Q, Liu Z, Yu X, Huang T, Chen J, Wang J, et al. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat Commun 2022; 13(1): 4981;","DOI":"10.1038\/s41467-022-32521-8"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Gallego A, Mendiola M, Hernando B, Berjon A, Cadiz A, Chaves-Urbano B, et al. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; 32(8): 1009-16;","DOI":"10.1136\/ijgc-2022-003353"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"William WN, Jr., Zhao X, Bianchi JJ, Lin HY, Cheng P , Lee JJ, et al. Immune evasion in HPV(-) head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss. Proceedings of the National Academy of Sciences of the United States of America 2021; 118(19);","DOI":"10.1073\/pnas.2022655118"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Korelacije P53, SLC7A11, CD3+ T \u0107elija i CD8+ T \u0107elija sa patolo\u0161kim karakteristikama i prognozom kod karcinoma endometrijuma - uvidi iz azijske kohorte"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/60128\/28534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582603663L.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:15:58Z","timestamp":1773782158000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582603663L"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-60128","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}